Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
In this phase I pilot study, it is planned to investigate the feasibility and safety of adding an interferon therapy to an preexisting imatinib treatment in patients with chronic phase chronic myeloid leukaemia. The participating patients have already reached a response during their imatinib therapy (CCyR) but have still a detectable disease (no molecular response MR 4.5 or better).
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Patients ≥ 18 years of age
BCR-ABL positive chronic myeloid leukaemia in chronic phase treated with imatinib as first line therapy
CHR, CCyR after at least 18 months of imatinib treatment
Adequate organ function, defined as the following:
Written, voluntarily signed informed consent
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
12 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal